Side-by-side research comparison of Cagrilintide and Semaglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 74 Cagrilintide studies and 1011 Semaglutide studies.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Drug class | amylin agonist | glp 1 agonist |
| Studies in corpus | 74 | 1011 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | rct · 38 other · 7 review · 7 in vitro · 1 preclinical animal · 2 meta analysis · 2 | n/a |
| Studies with explicit sample size | 13 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Cagrilintide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1198 Cagrilintide batches across 438 manufacturers, 99.55% avg purity.
We tested 1262 Semaglutide batches across 314 manufacturers, 99.55% avg purity.
We hold deeper lab coverage on Semaglutide (1262 batches tested). Average measured purity is effectively level (99.55% vs 99.55%).
Looking for vendor-level purity, endotoxin, and HPLC data on Cagrilintide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.